Autoimmune bullous skin disease
MONDO:0019337An autoimmune disease characterized by blisters on the skin.
Also known as: bullous skin disease, bullous dermatosis
86 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Can a targeted biologic outperform standard care for a rare blistering disease?
Disease control Not yet recruitingThis trial compares two treatment approaches for moderate to severe pemphigus vulgaris, a rare autoimmune disease causing painful blisters on skin and mucous membranes. One group receives rituximab (a biologic that targets immune B-cells) plus corticosteroids, while the other get…
Phase: EARLY_PHASE1 • Sponsor: Khyber Teaching Hospital • Aim: Disease control
Last updated Aug 18, 2026 06:00 UTC
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR-T injection aims to tame autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug STR-P005 aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for blistering skin diseases: drug targets antibodies to heal wounds
Disease control Not yet recruitingThis early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA)…
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Eye surgery breakthrough? tiny trial tests humira injection during corneal implant
Disease control Not yet recruitingThis early-stage trial will test whether injecting adalimumab (Humira) into the eye during Boston KPro surgery is safe for 8 patients with severe corneal damage. The study focuses on side effects and tolerability, not yet on how well it works. It is for people who have run out of…
Phase: PHASE1 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New shot could help patients with severe blistering skin disease ditch steroids
Disease control Not yet recruitingThis study tests an injection called stapokibart for people with moderate to severe bullous pemphigoid, a painful blistering skin condition. The goal is to see if it can help patients stop taking steroids and keep the disease under control for 36 weeks. About 200 adults aged 18 t…
Phase: PHASE3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immune system reset: CAR T-Cells take on autoimmune diseases
Disease control Not yet recruitingThis study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
Could one antibiotic dose before tooth pulling prevent infections in Immune-Weakened patients?
Prevention Not yet recruitingThis study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Yearly TB check may shield vulnerable patients from a hidden threat
Prevention Not yet recruitingThis trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 02, 2026 00:00 UTC
-
Statins vs. smoke: can a pill protect your heart and brain?
Knowledge-focused Not yet recruitingThis study tests whether taking statins (a common cholesterol drug) can protect the heart and brain from the harmful effects of breathing bushfire smoke. Healthy adults aged 18-64 will be exposed to simulated smoke in a controlled setting, with some taking statins short-term (2 d…
Phase: PHASE4 • Sponsor: Menzies Institute for Medical Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Can hospitals boost vaccine access for the most vulnerable?
Knowledge-focused Not yet recruitingThis study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC